Clinical trials: Body Weight Control
Overweight or Obesity Without Diabetes
Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without Diabetes
This study will test olatorepatide (study drug) to determine whether it can help treat overweight or obesity. In this study we will test how safe and how well olatorepatide works compared to placebo in people who are overweight…
- Trial name
- RISE-1 (NCT07896265)
- Testing
- Olatorepatide
- Volunteers
- 3,000 people
- Sponsor
- Regeneron Pharmaceuticals
Overweight and Obesity
Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese
A phase 2 study to evaluate the effects of apitegromab as an adjunctive therapy to GLP-1 receptor agonist therapy in subjects with overweight or obesity
- Trial name
- EMBRAZE (NCT06445075)
- Testing
- Apitegromab, Tirzepatide
- Where
- 7 sites in United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Scholar Rock, Inc.
Type 2 Diabetes, High Blood Pressure
Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients
Evaluation of safety, tolerability and superiority of RK-01, a valsartan plus celecoxib dual add-on to metformin-HCL XR over metformin in newly diagnosed and obese adult type 2 diabetes patients with high blood pressure…
- Conditions
- Type 2 Diabetes, High Blood Pressure, Arthritis, Obesity
- Trial name
- RESILIENCE (NCT03686657)
- Testing
- Metformin, Val, Cel and Met XR Low, Val, Cel and Met XR High
- Where
- United States
- Sponsor
- ARKAY Therapeutics
Muscle Function, Mitochondrial Function, Overweight
AMAZ-02 Effect on Exercise ToLerance in Healthy, Overweight Middle Aged Subjects (ATLAS Trial)
This is a Phase 2 randomized, double-blind, placebo-controlled study enrolling 90 healthy, overweight, middle aged subjects (30 placebo, 30 low dose and 30 high dose AMAZ-02 intervention), 40-65 years of age, who are otherwise…
- Conditions
- Muscle Function, Mitochondrial Function, Overweight, Healthy Aging
- Trial name
- ATLAS (NCT03464500)
- Testing
- Mitopure 500mg, Mitopure 1000mg
- Where
- Canada
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Amazentis SA
Dyslipidemia, Obesity
An International Study of Rimonabant in Dyslipidemia With AtheroGenic Risk In Abdominally Obese Patients
The purpose of this study is to assess the effect of rimonabant 20 mg on HDL (high density lipoprotein) cholesterol and on TG (triglycerides) plasma levels over a period of one year when prescribed with a hypocaloric diet (600…
- Trial name
- ADAGIO-lipids (NCT00239967)
- Testing
- Rimonabant (SR141716)
- Where
- 14 sites in United States, Australia and 12 more
- Volunteers
- 803 people
- Sponsor
- Sanofi
Obesity
A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity
This is a prospective, randomized, double-blind, placebo-controlled study designed to assess the safety and efficacy of bremelanotide (BMT) used in combination with tirzepatide therapy in the treatment of obesity in subjects with…
- Trial name
- BMT-801 (NCT06565611)
- Testing
- bremelanotide, tirzepatide
- Where
- 4 sites in United States
- Volunteers
- 108 people
- Sponsor
- Palatin Technologies, Inc
Obstructive Sleep Apnea, Obesity
UBT251 Injection Phase Ⅲ Study (OSA-PAP)
UBT251 will be compared with placebo (an inactive substance identical in appearance) to evaluate its therapeutic effect in participants with moderate-to-severe obstructive sleep apnea maintained on positive airway pressure…
- Trial name
- UNISHAPE-OSA-2 (NCT07806851)
- Testing
- UBT251
- Volunteers
- 150 people
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
Obesity
A Study to Evaluate the Safety and Efficacy of HSG4112 in Overweight and Obese Patients
1. Study Objective To assess the effect of HSG4112 on body weight To evaluate the safety and tolerability of HSG4112 2. Background Glaceum Inc.
- Trial name
- NCT05197556
- Testing
- HSG4112
- Where
- South Korea
- Volunteers
- 81 people
- Sponsor
- Glaceum
Obesity
Use of the Incisionless Operating Platform as a Primary Treatment for Obesity vs. Diet-Exercise Alone
This study is a multi-center, open/unblended study (3:1Treatment: Control) to evaluate the safety and effectiveness of the g-Cath EZ Suture Anchor Delivery Catheter as an early weight loss intervention compared to a diet and…
- Trial name
- MILEPOST (NCT01843231)
- Testing
- g-CathTM EZ Suture Anchor Delivery Catheter, Diet and Exercise Control Group
- Where
- 3 sites in Austria, Netherlands and 1 more
- Volunteers
- 40 people
- Sponsor
- USGI Medical
Type 1 Diabetes, T1D
DASH-Obesity: Explainable AI for Family-Centric Personalized Weight Control in Adolescents and Young Adults With Obesity and Chronic Conditions
This prospective single-arm feasibility study evaluates the Adhera Caring Digital Program for Obesity (ACDP-O), a family-centered digital health intervention designed to support adolescents and young adults with…
- Conditions
- Type 1 Diabetes, T1D, Obesity & Overweight, Obesity Type 2 Diabetes Mellitus
- Trial name
- DASH-Obesity (NCT07638345)
- Testing
- Adhera Caring Digital Program-Obesity (ACDP-O)
- Where
- Spain
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Adhera Health, Inc.
Obesity
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
This study will look at how well CagriSema helps people living with obesity to lose weight and maintain the weight loss long-term.
- Trial name
- NCT07011667
- Testing
- CagriSema (Cagrilintide B and Semaglutide I)
- Where
- 47 sites in United States
- Volunteers
- 609 people
- Sponsor
- Novo Nordisk A/S
Cachexia; Cancer, Non Small Cell Lung Cancer
A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - 2
The goal of this clinical trial was to compare the efficacy and safety of anamorelin HCl (the investigational drug) to that of placebo (tablet with no drug) in patients with advanced non-small cell lung cancer and cachexia…
- Trial name
- NCT03743064
- Testing
- anamorelin HCl
- Where
- 65 sites in United States, Australia and 6 more
- Volunteers
- 318 people
- Sponsor
- Helsinn Healthcare SA
Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities, Overweight (BMI > 25)
AIM-WEIGHT: AI-Guided Microbiome-Targeted Nutritional Intervention for Weight Loss
AIM-WEIGHT is a clinical study evaluating whether a fixed microbiome-targeted nutritional supplement can support weight loss in adults with overweight or obesity who do not have prediabetes or diabetes.
- Trial name
- AIM-WEIGHT (NCT07736547)
- Testing
- AI-Guided Microbiome-Targeted Nutritional Supplement, Lifestyle counselling
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people
- Sponsor
- Varol TUNALI
Type 2 Diabetes, Obesity
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
To determine if the EndoBarrier safely and effectively improves glycemic control in obese subjects with type 2 diabetes
- Trial name
- ENDO (NCT01728116)
- Testing
- EndoBarrier
- Where
- 25 sites in United States
- Volunteers
- 325 people
- Sponsor
- Morphic Medical Inc.
Insulin Resistance, Obesity
A Study of the Effect of INCB013739 on Cortisone Reducing Enzyme Activity in Obese People Predisposed to Diabetes
The purpose of this study is to determine whether the investigational drug INCB013739 has an effect on systemic and adipose tissue 11-HSD1 activity in obese, insulin resistant subjects.
- Trial name
- NCT00398619
- Testing
- INCB13739
- Where
- 2 sites in United States
- Sponsor
- Incyte Corporation
Congestive Heart Failure, Renal Impairment
A Study to Learn How the Study Treatment BAY1753011 Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body When Given Once as Tablet in Male and Female Participants With Reduced Kidney Function Compared to Matched Participants With Normal Kidney Function
Researchers are looking for a better way to treat people with heart failure. Heart failure is a condition which occurs when the heart does not pump blood as well as it should leading to shortness of breath, tiredness, and ankle…
- Trial name
- NCT05599997
- Testing
- Pecavaptan (BAY1753011)
- Where
- 2 sites in Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Bayer
Overweight or Obesity
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US
This study will test olatorepatide (study drug) to determine how safe and effective this drug is and how easily your body can accept this drug without causing side effects, as well as how the drug is processed in the body by…
- Trial name
- NCT07431086
- Testing
- Olatorepatide
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Regeneron Pharmaceuticals
Adolescents With Obesity, Adolescents With Overweight & Weight-related Comorbidities
A Study of Ecnoglutide Injection in Overweight or Obese Chinese Adolescents
The aim of the study is to evaluate the safety and efficacy of Ecnoglutide injection in overweight or obese Chinese adolescents
- Trial name
- NCT07836270
- Testing
- Ecnoglutide Injection
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
Obesity, Diabetes Mellitus, Type 2
A Study of the Efficacy and Safety of Topiramate in Obese, Type 2 Diabetic Patients Inadequately Controlled on Sulfonylurea Therapy
The purpose of this study is to compare the effectiveness and safety of topiramate with placebo in the treatment of obesity and Type 2 diabetes mellitus in patients who have failed on sulfonylurea therapy.
- Conditions
- Obesity, Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset
- Trial name
- NCT00231634
- Testing
- topiramate
- Volunteers
- 31 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Weight Loss
VK2735 for Weight Management Phase 3
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics…
- Trial name
- VANQUISH 1 (NCT07104500)
- Testing
- VK2735
- Where
- 137 sites in United States, Puerto Rico
- Volunteers
- 4,500 people
- Sponsor
- Viking Therapeutics, Inc.